Angiotensin 1-7 in Obesity Hypertension

Obesity Clinical Trial

Official title:

Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03604289
• Other study ID #: STUDY00008170
• Secondary ID: 18POST33960087
• Status: Terminated
• Phase: Early Phase 1
• Start date: April 1, 2019
• Est. completion date: June 3, 2023

Study information

• Verified date: June 2024
• Source: Milton S. Hershey Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out if the investigational drug angiotensin-(1-7) improves cardiovascular health in patients with obesity and high blood pressure.

Description:

Obesity is a major public health concern that greatly increases risk for developing cardiovascular disease. Importantly, obesity is associated with endothelial dysfunction and elevated sympathetic tone, vascular and autonomic derangements known to elevate blood pressure and increase cardiovascular risk. The renin-angiotensin system may explain cardiovascular complications in obesity. Angiotensin-(1-7) is a beneficial hormone that is reduced in obesity and restoration of this hormone improves endothelial function and reduces sympathetic activity in animal models, which may contribute to its blood pressure-lowering effects. The investigators will test the hypothesis that angiotensin-(1-7) improves cardiovascular function in humans with obesity hypertension. This hypothesis will be tested in a randomized, double blind, placebo-controlled crossover study. The investigators will measure the effects of acute intravenous angiotensin-(1-7) infusion on endothelial-mediated vasodilation in the brachial and coronary arteries and on blood pressure and muscle sympathetic nerve activity with direct microneurography recordings in obese hypertensive humans.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: June 3, 2023
• Est. primary completion date: May 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Men and women of all races

• Capable of giving informed consent

• Age 18-60 years

• Body mass index (BMI) between 30-40 kg/m2

• Hypertension defined as two or more seated blood pressure readings >130/80 mmHg or use of anti-hypertensive medications

• Satisfactory history and physical exam

Exclusion Criteria:

• Age = 17 or = 61 years

• Pregnant or nursing women

• Decisional impairment

• Prisoners

• Alcohol or drug abuse

• Current smokers

• Highly trained athletes

• Subjects with >5% weight change in the past 3 months

• Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)

• History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack).

• History or presence of immunological or hematological disorders

• Impaired hepatic function (AST or ALT levels >2 times upper limit of normal range)

• Impaired renal function (serum creatinine >2.0 mg/dl)

• Anemia

• Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors

• Treatment with phosphodiesterase-5 inhibitors

• Treatment with anticoagulants (e.g. warfarin)

• Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month)

• Treatment with any investigational drug in the 1-month preceding the study

• Inability to give, or withdraw, informed consent

Related Conditions & MeSH terms

• Hypertension
• Obesity

Intervention

Drug:
• Angiotensin-(1-7)
This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
• Saline
Saline will be used as the placebo comparator

Locations

Country	Name	City	State
United States	Penn State College of Medicine	Hershey	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Amy Arnold	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in brachial artery diameter with reactive hyperemia	A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound.	15 minutes including baseline, cuff inflation, and reactive hyperemia
Secondary	Heart Rate Variability	Resting heart rate variability will be calculated from baseline blood pressure recordings	30 minutes
Secondary	Circulating catecholamines	circulating catecholamines will be measured from blood samples	5 minutes
Secondary	Change in coronary blood velocity to the cold pressor test	Coronary blood velocity will be measured using duplex ultrasound before, during, and after cold pressor test (hand in ice water for 2 minutes)	20 minutes
Secondary	Change in systolic and diastolic blood pressure to the cold pressor test	Blood pressure will be measured continuously with a finger cuff before, during, and after the cold pressor test.	20 minutes
Secondary	Change in muscle sympathetic nerve activity to the cold pressor test	Muscle sympathetic nerve activity will be measured using peroneal nerve microneurography before, during, and after the cold pressor test.	20 minutes